Life Technologies completes previously announced acquisition of BioTrove

NewsGuard 100/100 Score
Dec 16 2009

Life Technologies Corporation (NASDAQ:LIFE), a provider of innovative life science solutions, today announced that it has completed the previously announced acquisition of BioTrove, Inc. for an undisclosed amount.

BioTrove’s primary technology is the OpenArray® platform, a high throughput gene expression and genotyping analysis system based on a flexible array format that enables researchers to perform more than 3,000 PCR genotyping or qPCR gene expression assays at a time.

As previously announced, Life Technologies does not expect this transaction to have a material effect on its financials in fiscal year 2009.

http://www.lifetechnologies.com/

Posted in:

Tags: , , , , , ,

Comments (0)

Suggested Reading

Study identifies genetic variants with profound impact on obesity risk
CASGEVY gene therapy eliminates vaso-occlusive crises in sickle cell patients
Adeno-associated virus: The gene therapy revolution faces manufacturing and safety hurdles
NYU Langone surgeons perform first combined mechanical heart pump and gene-edited pig kidney transplant surgery
Researchers elucidate how gene mutation mechanism causes autism
Researchers identify a ‘gene module’ involved in both depression and cardiovascular disease
Study reveals how genetic changes in SCN2A gene impact autism and epilepsy
Overdosing on chemo: A common gene test could save hundreds of lives each year

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Largest study of BRCA1 and BRCA2 carriers refines cancer risk estimates in Asian population